☆ 4.6 Letter

Pathological complete response to neoadjuvant pembrolizumab in a patient with metastatic cutaneous squamous cell carcinoma

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma

Virginia Ferraresi et al.

Summary: The success of immunotherapy and targeted therapy for metastatic melanoma has generated interest in adjuvant therapy for high-risk stage III melanoma. Immune checkpoint inhibitors activate tumor-reactive T cells to potentially prevent relapses.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

添加到收藏夹

Review Oncology

Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives

Andrea Alberti et al.

Summary: For patients with unresectable cutaneous squamous cell carcinomas (cSCCs), immunotherapy is an effective option, either alone or in combination with surgery or radiotherapy. It can improve the success rate of surgery in locally advanced cSCC and achieve long-term survival in some patients. However, resistance to immunotherapy remains a challenge, and new drugs and combination therapies are being studied to overcome this.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma

N. D. Gross et al.

Summary: This study evaluated the efficacy of cemiplimab as neoadjuvant therapy for resectable cutaneous squamous-cell carcinoma. The results showed a high percentage of patients achieved a pathological complete response with this treatment approach.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Review Oncology

Neoadjuvant immunotherapy for melanoma

Ann Y. Lee et al.

Summary: Clinical trials have shown the effectiveness of immunotherapy, particularly checkpoint inhibitors, in treating patients with metastatic melanoma. Recent reports indicate improved survival in high-risk resectable melanoma patients with adjuvant immunotherapy. Growing interest in neoadjuvant immunotherapy for high-risk resectable melanoma has been driven by early evidence of significant efficacy.

JOURNAL OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Review Oncology

Neoadjuvant Immunotherapy for High-Risk, Resectable Malignancies: Scientific Rationale and Clinical Challenges

Mithunah Krishnamoorthy et al.

Summary: Neoadjuvant immunotherapy shows promise in high-risk resectable diseases by increasing pathological response rate and prolonging relapse-free survival, with potential significance in preventing relapses. However, randomized controlled trials are needed to confirm its efficacy across different tumor types.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology